63121-00-6
63121-00-6 structure
- Name: Oxaliplatin
- Chemical Name: Platinum(2+) ethanedioate-1,2-cyclohexanediamine (1:1:1)
- CAS Number: 63121-00-6
- Molecular Formula: C8H14N2O4Pt
- Molecular Weight: 397.292
- Catalog: API Antineoplastic agents Other antineoplastic agents
- Create Date: 2018-06-20 17:21:30
- Modify Date: 2024-01-02 18:47:31
-
(rel)-Oxaliplatin is a DNA synthesis inhibitor. (rel)-Oxaliplatin causes DNA crosslinking damage, prevents DNA replication and transcription and induces apoptosis. (rel)-Oxaliplatin can be used for cancer research[1][2][3].
| Name | Platinum(2+) ethanedioate-1,2-cyclohexanediamine (1:1:1) |
|---|---|
| Synonyms |
Oxaliplatin
platinum, [ethanedioato(2-)-κO,κO]-, compd. with (1R,2R)-1,2-cyclohexanediamine (1:1) Platinum(2+) ethanedioate - (1R,2R)-1,2-cyclohexanediamine (1:1) Platinum(2+) ethanedioate (1R,2R)-1,2-cyclohexanediamine (1:1) [Ethanedioato(2-)-κO,O]platinum - (1R,2R)-cyclohexane-1,2-diamine (1:1) Platinum(2+) ethanedioate (1R,2R)-1,2-cyclohexanediamine (1:1:1) |
| Description | (rel)-Oxaliplatin is a DNA synthesis inhibitor. (rel)-Oxaliplatin causes DNA crosslinking damage, prevents DNA replication and transcription and induces apoptosis. (rel)-Oxaliplatin can be used for cancer research[1][2][3]. |
|---|---|
| Related Catalog | |
| In Vitro | (rel)-Oxaliplatin (24-72 hours; 2-128 μM; HCC, HCCLM3 and Hep3B cells) inhibits cell growth and induces apoptosis[1]. (rel)-Oxaliplatin (10 μM; 15-240 mins; CEM cells ) induces primary and secondary DNA lesions, including DNA cross-links (ISC) and DNA-protein cross-links (DPC)[2]. (rel)-Oxaliplatin (0.01 to 100 μM; 24 hours) potently inhibits bladder carcinoma cell lines RT4 and TCCSUP, ovarian carcinoma cell line A2780, colon carcinoma cell line HT-29, glioblastoma cell lines U-373MG and U-87MG, and melanoma cell lines SK-MEL-2 and HT-144 with IC50 of 11 μM, 15 μM, 0.17 μM, 0.97 μM, 2.95 μM, 17.6 μM, 30.9 μM and 7.85 μM, respectively[3] Cell Viability Assay[1] Cell Line: HCC, HCCLM3 and Hep3B cells Concentration: 24, 48 and 72 hours Incubation Time: 2, 4, 8, 16, 32, 64 and 128 μM Result: Decreased cell viability in a dose- and time-dependent manner. Western Blot Analysis[1] Cell Line: HCCLM3 and Hep3B cells Concentration: 48 hours Incubation Time: 10 μM Result: Down-regulated the expression of Bcl-2 and Bcl-xL, and increased the expression of Bax. Cell Cycle Analysis[1] Cell Line: HCCLM3 and Hep3B cells Concentration: 24 hours Incubation Time: 10 μM Result: Increased the percentage of apoptotic cells (17.70% for HCCLM3 cells; 21.19% for Hep3B cells). |
| In Vivo | (rel)-Oxaliplatin (5-10 mg/kg; i.p.; for 32 days; nude mice) inhibits tumor growth[1]. Animal Model: Nude mice[1] Dosage: 5 and 10 mg/kg Administration: Intraperitoneal injection; for 32 days Result: Reduced tumor volume in HCCLM3 tumor xenografts. |
| References |
| Boiling Point | 193.6ºC at 760 mmHg |
|---|---|
| Molecular Formula | C8H14N2O4Pt |
| Molecular Weight | 397.292 |
| Flash Point | 75ºC |
| Exact Mass | 397.060150 |
| PSA | 132.30000 |
| Storage condition | -20°C |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|